In the same study, blockade with either IL-4 neutralizing antibody or a mutant, inhibitory form of IL-4 (IL-4DM) reduced the viability of CD133+ and CD133− tumor cell cultures, while increasing the efficacy of cytotoxic treatment with standard chemotherapeutic agents: oxaliplatin, 5-fluorouracil, and the death receptor ligand TRAIL. The gene discussed is PROM1; the disease is neoplasm.